Stock Analiz

Editas Medicine, Inc. (EDIT) stock forecast and price target

Price $2.17 · data as of November 13, 2026

12-month price target

Average target$6.10
Upside / downside+181.1%
Analysts10
ConsensusBuy
Low $1.00Average $6.10High $15.00

Gold marker: average target · white marker: today’s price ($2.17)

Analyst ratings

Strong buy 0Buy 9Hold 2Sell 0Strong sell 2

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$-0.75+58.3%$33M
Next fiscal year
ends December 31, 2027
$-0.73+2.9%$21M
Next quarter
ends December 31, 2026
$-0.18−202.4%$7M
Quarter after
ends December 31, 2026
$-0.20−241.7%$2M

Consensus of the analysts covering Editas Medicine, updated daily. In the last 30 days 5 estimates were raised and 1 lowered.

Frequently asked questions

What is the Editas Medicine stock price target?

The average 12-month target from 10 analysts is $6.10, 181.1% above the current price of $2.17 Targets range from $1.00 to $15.00.

Is Editas Medicine a buy according to analysts?

The consensus rating is “Buy” (9 buy, 2 hold, 2 strong sell). Ratings are opinions, not guarantees; this is not investment advice.

How much is Editas Medicine expected to earn?

Analysts expect EPS of $-0.75 for the fiscal year ending December 31, 2026 and $-0.73 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.